Bellicum Pharmaceuticals (BLCM) Rating Reiterated by Raymond James Financial

Bellicum Pharmaceuticals (NASDAQ:BLCM)‘s stock had its “buy” rating restated by equities research analysts at Raymond James Financial in a research note issued to investors on Tuesday.

Several other analysts also recently weighed in on the company. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Jefferies Group reissued a “buy” rating and issued a $16.00 target price on shares of Bellicum Pharmaceuticals in a report on Thursday, September 14th. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, September 18th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $26.20.

Shares of Bellicum Pharmaceuticals (BLCM) opened at $8.87 on Tuesday. Bellicum Pharmaceuticals has a fifty-two week low of $7.41 and a fifty-two week high of $16.20. The company has a current ratio of 6.08, a quick ratio of 6.08 and a debt-to-equity ratio of 0.23.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.03. Bellicum Pharmaceuticals had a negative return on equity of 77.16% and a negative net margin of 17,957.31%. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period in the previous year, the business earned ($0.66) EPS. The business’s quarterly revenue was up 18.2% on a year-over-year basis. equities analysts predict that Bellicum Pharmaceuticals will post -2.93 EPS for the current fiscal year.

In related news, CFO Alan A. Musso sold 6,206 shares of the business’s stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $9.89, for a total value of $61,377.34. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Alan A. Musso sold 17,117 shares of the business’s stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $9.33, for a total value of $159,701.61. Following the completion of the transaction, the chief financial officer now owns 31,585 shares in the company, valued at approximately $294,688.05. The disclosure for this sale can be found here. Insiders own 18.77% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC acquired a new position in Bellicum Pharmaceuticals during the 2nd quarter worth approximately $132,000. Commonwealth Equity Services Inc acquired a new position in Bellicum Pharmaceuticals during the 3rd quarter worth approximately $142,000. Cubist Systematic Strategies LLC acquired a new position in Bellicum Pharmaceuticals during the 3rd quarter worth approximately $164,000. Nationwide Fund Advisors increased its position in Bellicum Pharmaceuticals by 30.4% during the 2nd quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,620 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Bellicum Pharmaceuticals during the 3rd quarter worth approximately $189,000. Institutional investors own 55.50% of the company’s stock.

WARNING: “Bellicum Pharmaceuticals (BLCM) Rating Reiterated by Raymond James Financial” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.com-unik.info/2017/12/14/bellicum-pharmaceuticals-blcm-rating-reiterated-by-raymond-james-financial.html.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit